P783: SYSTEMIC THERAPY UTILIZATION AND HEMATOLOGIC OUTCOMES IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FINDINGS FROM A REAL-WORLD MEDICAL RECORD REVIEW STUDY IN THE US, UK, AND EUROPE (EU)
M. Diez-Campelo,
A. Yucel,
R. Goyal,
R. C. Parikh,
S. Dhuliawala,
M. Jimenez,
M. Sluga-O’Callaghan,
C. Hughes,
D. Tang,
U. Germing
Affiliations
M. Diez-Campelo
1 Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain
A. Yucel
2 Bristol Myers Squibb, Princeton, NJ
R. Goyal
3 RTI Health Solutions, Research Triangle Park, NC, United States of America
R. C. Parikh
3 RTI Health Solutions, Research Triangle Park, NC, United States of America
S. Dhuliawala
3 RTI Health Solutions, Research Triangle Park, NC, United States of America
M. Jimenez
3 RTI Health Solutions, Research Triangle Park, NC, United States of America
M. Sluga-O’Callaghan
4 RTI Health Solutions, Lyon, France
C. Hughes
5 Bristol Myers Squibb, Summit, NJ, United States of America
D. Tang
2 Bristol Myers Squibb, Princeton, NJ
U. Germing
6 University Hospital of Dusseldorf, Dusseldorf, Germany
